FDA has granted an orphan drug designation to the active ingredient hypericin (HyBryte) for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma as previously granted.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe